Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.43 |
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | CCR5 | P51681 | 7/20 | 0.43 |
| ▸ | HTR2C | P28335 | 4/20 | 0.41 |
| ▸ | HTR7 | P34969 | 4/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5863558 | 0.88 | HDAC1 (0.49) | HTR2ADRD2HTR1ACCR5HTR2C | |
| SCHEMBL5863296 | 0.87 | CCR5 (0.46) | HTR2ADRD2HTR1ACCR5HTR2C | |
| SCHEMBL5863560 | 0.86 | CCR5 (0.45) | HTR2ADRD2HTR1ACCR5HTR2C | |
| SCHEMBL5863566 | 0.86 | CCR5 (0.45) | HTR2ADRD2HTR1ACCR5HTR2C | |
| SCHEMBL5863840 | 0.85 | TMEM97 (0.42) | HTR2ADRD2HTR1ACCR5HTR2C | |
| SCHEMBL5863838 | 0.85 | TMEM97 (0.42) | HTR2ADRD2HTR1ACCR5HTR2C | |
| SCHEMBL5864182 | 0.84 | OXTR (0.48) | HTR2ADRD2HTR1ACCR5 | |
| SCHEMBL5863847 | 0.84 | CCR5 (0.49) | HTR2ADRD2HTR1ACCR5HTR2C | |
| SCHEMBL5863822 | 0.84 | HTR2A (0.42) | HTR2ADRD2HTR1ACCR5HTR2C | |
| SCHEMBL5864115 | 0.83 | HTR2A (0.48) | HTR2ADRD2HTR1ACCR5HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030120-B2 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-04-18 | — | — | US | disclosed |
| US-20040224959-A1 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | OHKURA NAOTO (JP) | 2004-11-11 | — | — | US | disclosed |
| US-6777414-B1 | INHIBITORS OF TRIGLYCERIDE BIOSYNTHESIS AND SECRETION OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS; ARTERIOSCLEROTIC DISEASES; HYPERLIPIDEMIA | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-08-17 | — | — | US | disclosed |
| EP-1180514-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2002-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224959-A1 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | APOB, NCEH1, LIPC | HTR2A 1170/4885DRD2 625/4885HTR1A 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.